

## **Bionaut Labs - Revolutionizing Drug Delivery to the Brain**

**Company name:** Bionaut Labs                               **Website**     <https://bionautlabs.com/>  
**GM name-**                     Michael Kardosh

**Category:** Medical Devices

### **Sessions:**

- Unlocking a new era in brain health innovation
- Israeli medical contribution to breakthrough science and technology

### **Executive Summary / Investment Rational**

Bionaut is a first-in-class, remote-controlled, micro-scale robotic platform designed to treat critical conditions in the \$130B CNS Market, performing minimally invasive interventions on hard-to-reach body regions.

Conventional drug delivery methods grapple with blood-brain barrier limitations, resulting in limited localized efficacy and high systemic off-target side effects.

Bionaut technology enables treating various CNS conditions where current methods are limited.

### **Core Technology**

Bionaut's robots are smaller than a grain of rice and designed to deliver medication and monitor diseases throughout the body. They are controlled by external magnets, can be customized for different medical applications, offering a revolutionary approach to treating various CNS conditions.

### **Product Profile/Pipeline**

The company's pipeline today focuses on neuro-oncology, aiming to deliver targeted therapies for brain tumours.

Potential uses span localized treatment of conditions like cancer, neurodegenerative diseases, chronic pain, stroke, epilepsy and enabling precision microsurgery, biopsies and in vivo monitoring.

Bionaut's drug delivery platform enables precise, minimally invasive treatment delivery for a diverse range of therapeutics in the CNS.

### **What's Next?**

Bionaut has demonstrated pre-clinical safety in large animals and preparing for first clinical trials later in 2024.

Bionaut is collaborating with the world's leading hospitals, including Mayo Clinic, Boston Children's and the UC system and is backed by leading VC's in the Biotech field.